Head-to-head evidence
etanercept vs infliximab-qbtx (Ixifi)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
etanercept · Enbrel
Marketed by Amgen
NCT03780959 · Phase 2/3 · completed
After 90 days of open-label etanercept, 51 responding children were randomized to continue etanercept or receive placebo in a double-blind comparison. The clinical primary endpoint, disease flare, was met in favor of etanercept (28% vs 81% with placebo; p=0.0030), but the randomized sample was small, limiting the strength of the evidence.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
infliximab-qbtx (Ixifi)
Marketed by Pfizer
NCT02222493 · Phase 3 · completed
This was a randomized, quadruple-blinded, active-controlled Phase 3 equivalence trial in 650 adults with rheumatoid arthritis taking methotrexate, comparing PF-06438179 with infliximab. The primary endpoint was ACR20 response at Week 14, a clinical disease-activity measure: 61.1% with PF-06438179 versus 63.5% with infliximab, and the reported 95% confidence interval for the difference (-9.92 to 5.11) met the equivalence criterion, indicating no meaningful difference between treatments. This is strong evidence from a well-powered, blinded, controlled trial with a hard clinical endpoint and a met primary comparison.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: etanercept's landscape · infliximab-qbtx (Ixifi)'s landscape